Aspirin and tranexamic acid for coronary artery surgery trial. A collaborative project conducted by the Australian and New Zealand College of Anaesthetist Trials Group (ANZCA TG), and the NHMRC centre for clinical Research Excellence in Therapeutics - ATACAS

ational Health and Medical Research Council0 个研究点目标入组 4,600 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Males and females, age 18 years and over
•2.Written, informed consent
•3.Elective coronary artery surgery (on-pump or off-pump)
•4.Patient is at increased risk of major complications, defined by any of:
•Age >70 years
•Left ventricular impairment (fractional area change <20%, ejection fraction <40%, or at least moderate impairment on ventriculography)
•Concomitant valvular or aortic surgery
•Aneurysmectomy
•Repeat cardiac surgery (â??re-doâ??)
•Chronic obstructive pulmonary disease
•Renal impairment (se. creatinine >150 micromol/l or creatinine clearance <45 ml/min)
•Obesity (body mass index >25 kg/m2)
•Pulmonary hypertension (mPAP >25 mmHg)
•Peripheral vascular disease.

•1.Poor language comprehension
•2.Clinician preference for antifibrinolytic therapy
•3.Urgent surgery for unstable coronary syndromes where for clinical reasons antiplatelet medication cannot be discontinued
•4.Active peptic ulceration
•5.Allergy or contraindication to aspirin or tranexamic acid
•6.Aspirin therapy within 4 days of surgery
•7.Warfarin or clopidogrel therapy within 7 days of surgery, or GIIb/IIIa antagonists within 24 h of surgery
•8.Thrombocytopaenia or any other known history of bleeding disorder
•9.Severe renal impairment (serum creatinine 250 ï?mol/l, or estimated creatinine clearance 25 ml/min)
•10.Recent haematuria
•11.Thromboembolic disease relating to: history of postoperative or spontaneous pulmonary embolism, spontaneous arterial thrombosis or familial hypercoaguability (eg. Lupus anticoagulant, protein C deficiency)
•12.Pregnancy.

发起方

ational Health and Medical Research Council